157 related articles for article (PubMed ID: 23944378)
1. Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide.
Song Y; Zhang Y; Lee AR; Huang WH; Chen B; Palfey B; Shaw J
Curr Pharm Des; 2014; 20(1):146-52. PubMed ID: 23944378
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
3. Metabolism studies of a small-molecule tumor necrosis factor-alpha (TNF-α) inhibitor, UTL-5b (GBL-5b).
Shaw J; Shay B; Jiang J; Valeriote F; Chen B
Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):83-9. PubMed ID: 22052362
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
Heidarian R; Zahedi-Tabrizi M
Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
7. On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Kujawski J; Bernard MK; Jodłowska E; Czaja K; Drabińska B
J Mol Model; 2015 May; 21(5):105. PubMed ID: 25851105
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
Jiang L; Zhang W; Li W; Ling C; Jiang M
Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931
[TBL] [Abstract][Full Text] [Related]
10. Detection of in Vitro Metabolite Formation of Leflunomide: A Fluorescence Dynamics and Electronic Structure Study.
Sharma P; Gangopadhyay D; Mishra PC; Mishra H; Singh RK
J Med Chem; 2016 Apr; 59(7):3418-26. PubMed ID: 27007481
[TBL] [Abstract][Full Text] [Related]
11. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
12. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
13. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.
Fuentealba RA; Marasa J; Diamond MI; Piwnica-Worms D; Weihl CC
Hum Mol Genet; 2012 Feb; 21(3):664-80. PubMed ID: 22052286
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
17. The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis.
Millar JA
N Z Med J; 2019 Feb; 132(1490):36-41. PubMed ID: 30789887
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and Anti-arthritic Effects of a Novel Leflunomide Analogue, UTL-5b (GBL-5b).
Shaw J; Chen B; Wooley P; Huang WH; Lee AR; Zeng D
Am J Biomed Sci; 2011 Jan; 3(1):31-39. PubMed ID: 21253441
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.
Wu J; Shaw J; Dubaisi S; Valeriote F; Li J
Drug Metab Dispos; 2014 Dec; 42(12):2058-67. PubMed ID: 25249693
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.
Zeyda M; Poglitsch M; Geyeregger R; Smolen JS; Zlabinger GJ; Hörl WH; Waldhäusl W; Stulnig TM; Säemann MD
Arthritis Rheum; 2005 Sep; 52(9):2730-9. PubMed ID: 16142756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
